/
Innoviva, Inc. ( Innoviva , the Company , the Registrant or we and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ( IST ), and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group…
$21.32
$0.39 (-1.80%)
Live · 06:15 PM
39.81% operating margin is above average. ROIC at 8.36%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue up 14.7% YoY with margins expanding 29.4pp.
Even for strong businesses, today's 3x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
3.4x earnings, 9.9x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$421M
▲ +14.7% YoY
Net Income (TTM)
$504M
▲ +1059.2% YoY
Op. Margin
38.14%
▲ +29.4pp YoY
ROIC
9.24%
▲ +6.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$184M
▲ +3.9% YoY
Op. Cash Flow (TTM)
$184M
▲ +4.4% YoY
Net Debt
-$334M
Net Cash Position
Cash & Equiv.
$603M
5Y CAGR: +4.1%
5Y CAGR: -9.0%
Continue Research
At a P/E of 3.4 and a price-to-free-cash-flow of 9.9, Innoviva (INVA) trades below a two-stage DCF intrinsic value of about $41.43 per share, so at $21.32 the stock looks undervalued (94.3% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Innoviva scores 60/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $41.43 per share for INVA, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $31.07. At today's $21.32, that puts the stock about 94.3% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Innoviva scores 60 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 38.1% operating margin and a 9.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. INVA currently trades below its estimated intrinsic value and scores 60/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.